Highlights From the American Diabetes Association Scientific Session 2023

Data on a new crop of hormone analogues for weight loss—including an oral version of semaglutide and the triple agent retatrutide—were recently presented at the American Diabetes Association’s annual Scientific Sessions. Robert Gabbay, MD, PhD, the ADA’s chief scientific and medical officer, speaks with JAMA’s Jennifer Abbasi about this and other clinical data presented at the meeting. Related Content:

• New Weight Loss Drugs Make Headlines at Diabetes Meeting